​

Centessa Pharmaceuticals (CNTA) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChart

CNTA Stock Forecast

Centessa Pharmaceuticals (CNTA) stock forecast, based on 8 Wall Street analysts, predicts a 12-month average price target of $22.33, with a high of $31.00 and a low of $6.00. This represents a -1.50% decline from the last price of $22.67.

$5 $11 $17 $23 $29 $35 High: $31 Avg: $22.33 Low: $6 Last Closed Price: $22.67

CNTA Stock Rating

Centessa Pharmaceuticals stock's rating consensus is Buy, based on 8 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 7 Buy (87.50%), 1 Hold (12.50%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 8 0 1 7 Strong Sell Sell Hold Buy Strong Buy

CNTA Price Target Upside V Benchmarks

TypeNameUpside
StockCentessa Pharmaceuticals-1.50%
SectorHealthcare Stocks 13.55%
IndustryBiotech Stocks 49.00%

Price Target Trends

1M3M12M
# Anlaysts116
Avg Price Target$31.00$31.00$24.67
Last Closing Price$22.67$22.67$22.67
Upside/Downside36.74%36.74%8.82%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Sep, 2529---11
Aug, 2539---12
Jul, 2547---11
Jun, 2548---12
May, 2537---10
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Sep 02, 2025Wells Fargo$31.00$17.2779.50%36.74%
May 08, 2025Rudy LiChardan Capital$30.00$12.41141.74%32.33%
May 08, 2025Andreas ArgyridesOppenheimer$6.00$12.41-51.65%-73.53%
Mar 07, 2025Morgan Stanley$27.00$16.2366.36%19.10%
Nov 15, 2024Debjit ChattopadhyayGuggenheim$28.00$17.1063.74%23.51%
Sep 19, 2024Jeffrey HungMorgan Stanley$26.00$15.8564.04%14.69%
Sep 11, 2024Kelly ShiJefferies$19.00$14.9926.75%-16.19%
Sep 10, 2024Kostas BiliourisBMO Capital$20.00$16.0224.84%-11.78%
Aug 14, 2024Kostas BiliourisBMO Capital$15.00$12.6019.05%-33.83%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Sep 02, 2025Wells FargoOverweightinitialise
May 08, 2025OppenheimerOutperformOutperforminitialise
Nov 15, 2024GuggenheimBuyBuyhold
Sep 19, 2024Morgan StanleyEqual-WeightOverweightupgrade
Sep 18, 2024B. RileyBuyinitialise
Sep 11, 2024JefferiesBuyBuyhold
Sep 11, 2024GuggenheimBuyBuyhold
Sep 09, 2024BMO CapitalOutperformOutperformhold
Aug 14, 2024BMO CapitalOutperformOutperformhold
Jul 18, 2024OppenheimerOutperforminitialise

Financial Forecast

EPS Forecast

Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-1.57$-2.06----
Avg Forecast$-1.63$-1.52$-1.55$-1.73$-2.03$-1.24
High Forecast$-1.57$-1.43$-1.12$-1.07$-1.11$-1.24
Low Forecast$-1.69$-1.78$-1.81$-2.00$-2.62$-1.24
Surprise %-3.68%35.53%----

Revenue Forecast

$0 $30M $60M $90M $120M $150M Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$6.85M-----
Avg Forecast$6.85M$6.85M$269.50K$3.78M$40.90M$148.00M
High Forecast$6.85M$6.85M$269.75K$3.78M$40.90M$148.00M
Low Forecast$6.85M$6.85M$269.25K$3.78M$40.90M$148.00M
Surprise %------

Net Income Forecast

$-300M $-260M $-220M $-180M $-140M $-100M Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-151.09M$-235.76M----
Avg Forecast$-151.09M$-161.26M$-141.22M$-147.35M$-251.32M$-118.94M
High Forecast$-150.62M$-137.35M$-108.02M$-102.63M$-106.36M$-118.94M
Low Forecast$-162.13M$-171.23M$-174.41M$-192.06M$-251.91M$-118.94M
Surprise %-46.19%----

CNTA Forecast FAQ

Is Centessa Pharmaceuticals stock a buy?

Centessa Pharmaceuticals stock has a consensus rating of Buy, based on 8 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 7 Buy, 1 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Centessa Pharmaceuticals is a favorable investment for most analysts.

What is Centessa Pharmaceuticals's price target?

Centessa Pharmaceuticals's price target, set by 8 Wall Street analysts, averages $22.33 over the next 12 months. The price target range spans from $6 at the low end to $31 at the high end, suggesting a potential -1.50% change from the previous closing price of $22.67.

How does Centessa Pharmaceuticals stock forecast compare to its benchmarks?

Centessa Pharmaceuticals's stock forecast shows a -1.50% downside, underperforming the average forecast for the healthcare stocks sector (13.55%) and underperforming the biotech stocks industry (49.00%).

What is the breakdown of analyst ratings for Centessa Pharmaceuticals over the past three months?

  • September 2025: 18.18% Strong Buy, 81.82% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • August 2025: 25.00% Strong Buy, 75.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • July 2025: 36.36% Strong Buy, 63.64% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is Centessa Pharmaceuticals’s EPS forecast?

Centessa Pharmaceuticals's average annual EPS forecast for its fiscal year ending in December 2025 is $-1.55, marking a -24.76% decrease from the reported $-2.06 in 2024. Estimates for the following years are $-1.73 in 2026, $-2.03 in 2027, and $-1.24 in 2028.

What is Centessa Pharmaceuticals’s revenue forecast?

Centessa Pharmaceuticals's average annual revenue forecast for its fiscal year ending in December 2025 is $269.5K, reflecting a 0% decrease from the reported $0 in 2024. The forecast for 2026 is $3.78M, followed by $40.9M for 2027, and $148M for 2028.

What is Centessa Pharmaceuticals’s net income forecast?

Centessa Pharmaceuticals's net income forecast for the fiscal year ending in December 2025 stands at $-141M, representing a -40.10% decrease from the reported $-236M in 2024. Projections indicate $-147M in 2026, $-251M in 2027, and $-119M in 2028.